Demographic details of the entire cohort, and patients without (F0–2) and with (F3–4) advanced fibrosis
| Entire cohort (N=5735) | F0–2 (N=4013) | F3–4 (N=1722) | |
| Females (%) | 45 | 43 | 48 |
| BMI ≥30 kg/m2 (%) | 43 | 45 | 53 |
| Waist circumference (cm) | 103 (15) | 102 (15) | 106 (14) |
| Diabetes (%) | 33 | 30 | 58 |
| Age (years)* | 54 (19) | 50 (19) | 59 (14) |
| BMI (kg/m2)* | 30 (7) | 29 (8) | 30 (7) |
| Biopsy data | |||
| Steatosis | |||
| S0/S1/S2/S3 (%) | 3/35/36/26 | 3/36/36/25 | 2/32/38/28 |
| Ballooning | |||
| B0/B1/B2 (%) | 24/47/29 | 30/49/21 | 10/45/45 |
| Inflammation | |||
| I0/I1/I2/I3 (%) | 13/60/24/3 | 17/62/20/1 | 5/55/34/6 |
| NAS score† | 4 (2) | 4 (2) | 5 (1) |
| NASH (%) | 50 | 43 | 67 |
| Liver function tests | |||
| ALT (IU/L)* | 55 (48) | 53 (48) | 60 (48) |
| AST (IU/L)* | 40 (30) | 36 (25) | 50 (34) |
| Platelets (×109/L)† | 230 (72) | 241 (67) | 205 (75) |
| Albumin (g/L)† | 43 (9) | 43 (7) | 43 (13) |
| GGT (IU/L)* | 69 (87) | 62 (78) | 87 (102) |
| NITs | |||
| LSM (kPa)* | 10.7 (6.1) | 6.7 (3.5) | 13.3 (12.0) |
| FIB-4* | 1.7 (1.2) | 1.1 (0.9) | 1.9 (1.7) |
| NFS† | −1.5 (1.7) | −1.9 (1.6) | −0.6 (1.8) |
| APRI* | 0.6 (0.4) | 0.4 (0.3) | 0.6 (0.6) |
| AST/ALT* | 0.8 (0.4) | 0.7 (0.4) | 0.8 (0.5) |
*Data are reported as median (IQR).
†Data are reported as mean (SD).
ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index ; FIB-4, Fibrosis-4 Index; GGT, gamma-glutamyltransferase; LSM, liver stiffness measurement; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; NFS, NAFLD (non-alcoholic fatty liver disease) Fibrosis Score; NIT, non-invasive test.